2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.27 USD
-0.36 (-7.78%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.28 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
2seventy bio, Inc. (TSVT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.33 | $25.00 | $5.00 | 166.31% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for 2seventy bio, Inc. comes to $12.33. The forecasts range from a low of $5.00 to a high of $25.00. The average price target represents an increase of 166.31% from the last closing price of $4.63.
Analyst Price Targets (6 )
Broker Rating
2seventy bio, Inc. currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.43 | 2.43 | 2.43 | 2.43 | 2.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/18/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
1/31/2024 | SVB Securities | Daina M Graybosch | Hold | Strong Buy |
9/12/2023 | Guggenheim Securities | Kelsey Goodwin | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 7 |
Average Target Price | $12.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -0.72 |